Why Moderna Stock Fell 32% in December

1 min read

Shares of biotech Moderna (NASDAQ: MRNA), maker of a COVID-19 vaccine, dropped 31.6% in December, according to data from S&P Global Market Intelligence

For context, the S&P 500 returned 3.8% last month.

Image source: Getty Images.

Continue reading

Leave a Reply

Your email address will not be published.

Previous Story

Why CrowdStrike, FireEye, and Zscaler Surged as Much as 48.7% in December

Next Story

Should Investors Be Worried About Pfizer and BioNTech’s Coronavirus Vaccine Rollout?

Latest from Blog